|
Conference Synopsis
BioMedical Asia 2008 will feature 6 great conferences dedicated to Asia's growing Biomedical industry.
 is the FIRST and ONLY event in the region bringing together bioinformatics opinion leaders, technology providers, researchers and R&D leaders from the pharmaceutical and biotech industry and academia to discuss the cutting edge bioinformatics technology and its commercial applications in modern biomedical research and drug discovery.
 will bring together global biopharmaceutical companies with biotechs and research institutions in Asia to discuss strategic issues on licensing, technology transfer, IP rights and partnership models. This will be the only platform in Asia where biotechs showcase their latest technologies and innovations.
 is the first of its kind, bringing together pharmaceutical manufacturers, clinical research organizations, biotechs and logistic solution providers from across Asia to discuss the best supply models and practices for the biomedical industry of Asia.
 At a time of escalating demand for biologic drugs from Asia, whilst Asia’s talent pool and regulatory infrastructure is maturing, BioManufacturing Asia 2008 will bring together international and regional biologic manufacturers, start-up & spin-off biotechs, research and academic institutions, contract manufacturing service providers, technology and solution providers to discuss biopharmaceutical manufacturing opportunities and trends, best business strategies and practices, development and manufacturing technology advancement and its implementation in Asia.
 will bring together private equities, venture capitalists, biotech funds and other professional investors with leading public and private biotech companies with new drugs, diagnostics and medical technologies from Asia and globally, to explore investment opportunities offered by the burgeoning Asia’s biomedical industry. This will be the only event in Asia where capital meets new business opportunities.
 Biotherapeutics are forecast to be the fastest growing sector of the pharmaceutical industry, with big pharmaceutical companies estimated to be generating around 60% of revenue through biologic products by 2010. Meanwhile, the cost of drug development continues to rise and development time continues to lengthen. With its diverse patient pool, growing market share, increasing quality talents and inexpensive cost, Asia has been chosen by many global pharmas and biotechs as an important strategic location for cost effective drug development. Biotherapeutics Asia will serve as a timely platform bringing together regulators, researchers, pre-clinical and clinical development professionals from biopharmaceutical companies across Asia Pacific and globally to learn and discuss the best strategies and practices to fast-track new generation biotherapeutics development to market in Asia.
|
